113 related articles for article (PubMed ID: 15317145)
21. A turbulent year at the agency.
Ratner M
Nat Biotechnol; 2006 Feb; 24(2):145-51. PubMed ID: 16465153
[No Abstract] [Full Text] [Related]
22. Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration.
Jiao K; Gupta R; Fox E; Kesselheim A; Ross JS
JAMA Netw Open; 2019 Oct; 2(10):e1913029. PubMed ID: 31603482
[TBL] [Abstract][Full Text] [Related]
23. New drug approvals for 2002.
Frantz S; Smith A
Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
[No Abstract] [Full Text] [Related]
24. New leadership for the FDA.
Lancet; 2002 Oct; 360(9341):1183. PubMed ID: 12401238
[No Abstract] [Full Text] [Related]
25. Biotech hits regulatory doldrums.
Lawrence S
Nat Biotechnol; 2005 Jun; 23(6):644. PubMed ID: 15940226
[No Abstract] [Full Text] [Related]
26. FDA leadership picks may stress safety over swift approval.
Dorans K
Nat Med; 2009 May; 15(5):466. PubMed ID: 19424185
[No Abstract] [Full Text] [Related]
27. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.
Cross J; Lee H; Westelinck A; Nelson J; Grudzinskas C; Peck C
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):439-46. PubMed ID: 12426927
[TBL] [Abstract][Full Text] [Related]
28. FDA publishes analysis of the pipeline problem.
Frantz S
Nat Rev Drug Discov; 2004 May; 3(5):379. PubMed ID: 15152628
[No Abstract] [Full Text] [Related]
29. Concerns raised over declining antiinfectives R&D.
Fox JL
Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
[No Abstract] [Full Text] [Related]
30. FDA approval of oncology drug indications, 1949-2015.
Manag Care; 2015 Oct; 24(10):41. PubMed ID: 26665713
[No Abstract] [Full Text] [Related]
31. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC
Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252
[TBL] [Abstract][Full Text] [Related]
32. FDA begins product approval initiative.
Lewis C
FDA Consum; 2003; 37(3):10-1. PubMed ID: 12793386
[No Abstract] [Full Text] [Related]
33. Vioxx fears prompt call for user fee evaluation.
Frantz S
Nat Rev Drug Discov; 2005 Mar; 4(3):179. PubMed ID: 15770775
[No Abstract] [Full Text] [Related]
34. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997.
Kulynych J
Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555
[No Abstract] [Full Text] [Related]
35. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.
Alper K; Schwartz KA; Kolts RL; Khan A
Biol Psychiatry; 2007 Aug; 62(4):345-54. PubMed ID: 17223086
[TBL] [Abstract][Full Text] [Related]
36. FDA evaluates accelerated approval process. Food and Drug Administration.
Common Factor; 1995 Apr; (no 10):18. PubMed ID: 11362343
[TBL] [Abstract][Full Text] [Related]
37. Drug pipeline: Q310.
Peng W
Nat Biotechnol; 2010 Oct; 28(10):998. PubMed ID: 20944578
[No Abstract] [Full Text] [Related]
38. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2008; 21(1):36-43. PubMed ID: 18301808
[TBL] [Abstract][Full Text] [Related]
39. Failure rate and "professional subjects" in clinical trials of major depressive disorder.
Shiovitz TM; Zarrow ME; Shiovitz AM; Bystritsky AM
J Clin Psychiatry; 2011 Sep; 72(9):1284; author reply 1284-5. PubMed ID: 21951988
[No Abstract] [Full Text] [Related]
40. FDA issues regulations on accelerated drug-approval process.
Clin Pharm; 1993 Apr; 12(4):253-4. PubMed ID: 8458175
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
